Results 31 to 40 of about 21,523 (174)

Epidemiology of Cancer‐Associated Venous Thromboembolism Across the United States

American Journal of Hematology, EarlyView.
ABSTRACT Prior epidemiological studies on cancer‐associated venous thromboembolism (VTE) were limited by homogenous patient populations. We leverage Cosmos, a collaborative dataset of Epic electronic health record systems, to conduct an updated evaluation of cancer‐associated VTE in the United States (US).
Barbara D. Lam, Justine Ryu, Omid Jafari, Rock Bum Kim, Shengling Ma, Mrinal Ranjan, Jun Y. Jiang, Ang Li   +7 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

Presente y futuro del tratamiento anticoagulante oral [PDF]

, 2014
The alternative new oral anticoagulants open a new era in antithrombotic treatment. For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders.
García Frade, Luis Javier
core   +1 more source

Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher, Richard Buka, Rosalind Byrne, Stephen Black, Helen J. Curtis, Christopher Wood, Andrew Brown, Sebastian Bacon, Richard Croker, Ben Goldacre, Brian MacKenna, Victoria Speed   +11 more
wiley   +1 more source

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways

BMC Pharmacology and Toxicology, 2019
Background Apixaban effectively lowers the risk of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. Systemic exposure to a given apixaban dose depends on multiple clearance pathways.
Andrea Huppertz, Caspar Grond-Ginsbach, Chris Dumschat, Kathrin I. Foerster, Jürgen Burhenne, Johanna Weiss, David Czock, Jan C. Purrucker, Timolaos Rizos, Walter E. Haefeli   +9 more
doaj   +1 more source

Perspectivas clínicas del manejo de la hemorragia en el paciente tratado con anticoagulante oral: estudio DECOVER [PDF]

, 2018
Objetivo. Evaluar el grado de acuerdo entre hematólogos y urgenciólogos respecto a las mejores prácticas para el manejo de hemorragias y la reversión de la anticoagulación oral. Método.
Camats, Míriam, Coll-Vinent i Puig, Blanca, Crespo Palomo, Carlos, González-Porras, José Ramón, Grupo DECOVER, Lecumberri, Ramón, Marco, Pascual, Martín, Alfonso, Mateo, José, Roldán, Vanesa, Soulard, Stéphane, Suero, Coral, Vicente, Vicente   +12 more
core  

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration

Frontiers in Veterinary Science, 2018
Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while ...
Priscila B. S. Serpa, Marjory B. Brooks, Thomas Divers, Sally Ness, Ingvild Birschmann, Mark G. Papich, Tracy Stokol   +6 more
doaj   +1 more source

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels

Research and Practice in Thrombosis and Haemostasis, 2021
Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer‐associated thrombosis (CAT) as reported in the ADAM‐VTE and Caravaggio studies, which ...
Verónica Bravo Villa, Job Romero, Eunice Rojas‐Zaldivar, Martha Cervantes, María del Rosario Villa‐Márquez, Patricia Baz, Gabriela Cesarman‐Maus   +6 more
doaj   +1 more source

Management of severe bone loss in patients at risk of medication‐related osteonecrosis of the jaw with microsurgery and guided bone regeneration: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira, José Maurício Paradella de Camargo, Lara Maria Alencar Ramos Innocentini, Ana Carolina Fragoso Motta   +3 more
wiley   +1 more source